Thrombosis, Hemostasis, and Cardiovascular Outcomes

Venous and arterial thromboembolism accounts for one of the highest burdens of cardiovascular morbidity and mortality. Appropriate and timely management of thromboembolism has considerable significance in contemporary clinical practice. Many pharmacological agents have been developed to treat thrombosis - the advent of newer catheterbased options has allowed minimally invasive catheter-based therapy to be provided safely to sick patients with lower bleeding risk and good efficacy. The physiologic pathways and clinical outcomes of thromboembolism and hemostasis are intricately linked, and our understanding of these interconnected processes has improved greatly in the past two decades. In this chapter, we will discuss the pathophysiology, epidemiology, and clinical features of thromboembolism and hemostasis, and their impact on cardiovascular outcomes. We will also review the commonly used drugs and catheter-based treatments for thromboembolic diseases. Lastly, we will discuss thrombosis associated with the novel Coronavirus 2019 disease and strategies for optimal hemostasis related to this condition.